A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

Who May Qualify: - Male (based on chromosomal composition at birth) and aged greater than or equal to (\>=) 18 years. - Must have a diagnosed by tissue sample (biopsy-confirmed) diagnosis of prostate adenocarcinoma - Must have documented metastatic hormone-sensitive prostate cancer (mHSPC) - Must have agreed with the treating physician to initiate treatment with apalutamide (plus androgen-deprivation therapy \[ADT\]) in accordance with the current product characteristics summary, based on the physician's decision, prior to study inclusion - Able to understand the content of the patient information sheet and has provided oral consent for data collection. Has received the information sheet and has not objected to data collection - Must have a baseline prostate-specific antigen (PSA) level collected prior to the first administration of apalutamide. - Must agree to complete adherence and quality-of-life questionnaires during the study, including before the first administration of apalutamide Who Should NOT Join This Trial: - Has already received or is currently receiving apalutamide, or any other androgen receptor pathway inhibitor (ARPI; including but not limited to abiraterone acetate, darolutamide, and enzalutamide) or chemotherapy for mHSPC - Has received an investigational drug (including vaccines) or used an invasive investigational medical device within 90 days prior to study start or data collection - Is currently receiving active treatment for prostate cancer as part of an interventional study - Has received ADT for mHSPC for more than 4 months prior to starting apalutamide treatment - Has experienced progression under ADT (and thus became castration-resistant) before starting apalutamide treatment - Beneficiary of State Medical Aid \[AME\] - Does not speak/read French - Under guardianship or curatorship - Under judicial protection Always talk to your doctor about whether this trial is right for you.